Chun-Hao Huang, PhD

San Francisco, United States
Dr. Chun-Hao Huang is Co-Founder & CEO of Algen. Dr. Huang is a genetic engineer and drug developer. He received his postdoctoral training at UC Berkeley under the mentorship of Nobel Laureate Jennifer Doudna, and his Ph.D. at Memorial Sloan-Kettering Cancer Center/Weill Cornell Medicine under the mentorship of Professors Scott Lowe and Charles Sherr. Dr. Huang pioneered genetically engineered models using CRISPR and RNAi, which led to the discovery of new therapeutic strategies for treating cancer and inflammatory diseases. He also invented methods to identify disease biomarkers that predict drug responses, and applied machine learning to the study of genes. Dr. Huang is UN’s Sustainable Development Goals Talent of the UNLEASH Innovation Lab, Fellow of the 64th Lindau Nobel Laureate Meeting and AACR Basic Cancer Research. He has authored over 40 scientific papers and 2,500 citations across top-tier journals including Cell, Science, and Nature Biotechnology.
Speaking In
2:45 PM - 3:00 PM
Wednesday, June 7
Algen is a platform therapeutics and drug discovery company using the world’s leading CRISPR and AI…
Session Room 103